TREATMENT AND PREVENTION OF COMBINED CARDIO-RESPIRATORY PATHOLOGY IN EXACERBATION OF CHRONIC OBSTRUCTIVE-PULMONARY DISEASE (new approach)
Abstract
The features of the course of exacerbations of chronic obstructive pulmonary disease (COPD) in combination with coronary heart disease in the form of stable angina, and with the threat of destabilizing its course. The changes of the cardiovascular system in patients with a background of clinical symptoms in patients with acute exacerbation of COPD II-III stages. A differentiated approaches to anti-inflammatory and cardio protective action of drug combinations Roflumilast and quercetin as components of adjuvant therapy in patients with combined cardiovascular disease.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Quercetin Influences Quorum Sensing in Food Borne Bacteria: In-Vitro and In-Silico Evidence
- Phenolic-protein interactions: insight from in-silico analyses – a review
- In Silico Discovery of Candidate Drugs against Covid-19
- Neuropharmacological Effects of Quercetin: A Literature-Based Review
- In vitro and in silico anti-dengue activity of compounds obtained from Psidium guajava through bioprospecting
- Effect of Quercetin Rich Onion Extracts on Bacterial Quorum Sensing
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.